Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEM1: NVA237 in Stable COPD
NCT01709864Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2012
- Primary completion
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing NVA237 with Placebo (2 arms). Primary endpoint: Standardized Area Under the Curve (AUC) for Forced Expiratory Volume in One Second (FEV1) Post Dosing at 12 weeks. Started Nov 2012; status: completed.
02
Drugs
glycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01709864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01709864.